 Disorders of Short Stature
Pediatric Growth Hormone Deficiency
Adult Growth Hormone Deficiency
Researchers Corner
rGH Pharmaceutical Manufacturers
Links to Organizations & Information
Clinical Trials and Studies
Medical Insurance Issues
Pediatric Discussion Forum
Adult Discussion Forum
Annual Research Grant Program
HGF Gift Giving Program
Short and OK
Ready for School
Patterns of Growth
rowth Hormone Deficiency
Turner Syndrome
Join the Human Growt Foundation
PAY ON-LINE WITH PAYPAL
It's fast, free and secure!
A PayPal account is not required.
All major credit cards are accepted.
Simply click the "DONATE" button below.
Enduring and Rewarding Gifting!
Merchants donate to HGF at no cost to you. Your donations are tax deductible! Click on the iGIVE.COM icon below, sign up, install the tool bar, and you are good to go! Tell your family and friends!
(Click on the Bears)
Please see our first product for sale in the new HGF Retail Store: A beautiful music extended play (EP) CD that children and families will love.
|
|
On July 26, 2003, the federal Food and Drug Administration approved a supplemental new drug application by Eli Lilly & Company for the use of human growth hormone to treat children who are healthy but unusually short (defined as an adult height of less than 5 feet 3 inches for men and 4 feet 11 inches for women) without a known cause. This approval makes rGH available to short children who may suffer from, but cannot demonstrate, a medical condition that is responsible for short stature.
The FDA based its decision on studies that found the biosynthesized hormone Humatrope added between one and three inches in height to children who took it for four to six years, and that there were no significant health risks for the children. The FDA decision followed the recommendation of an advisory panel last month that voted 8 to 2 in favor of approving the new usage of the drug. The approval could significantly increase the number of children who receive rGH, which can cost $30,000 to $40,000 a year. The effect of the expanded use of rGH on its cost to patients and on insurance coverage is not yet clear. The medical profession is split on this expansion of the use of rGH. Critics argue that the expanded use of rGH is likely to be misused for non-health reasons.
|
